Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis PharmacoEconomics Open (2018) 2:209–219 https://doi.org/10.1007/s41669-017-0050-3 OR IGINAL RESEARCH ARTIC L E Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis 1 2 3 4 • • • • Bernard Charbonnel Dominique Simon Jean Dallongeville Isabelle Bureau 5 5 6 4 • • • Sylvie Dejager Laurie Levy-Bachelot Julie Gourmelen Bruno Detournay Published online: 7 August 2017 The Author(s) 2017. This article is an open access publication Abstract 12.5; 53.9% male) matched with a control group of 76,406 Objectives Our objects was to estimate the direct health- individuals without diabetes. Overall per patient per year care costs of type 2 diabetes mellitus (T2DM) in France in medical expenditures were €6506 ± 10,106 in the T2DM 2013. group as compared with €3668 ± 6954 in the control group. Methods Data were drawn from a random sample of The cost difference between the two groups was €2838 per &600,000 patients registered in the French national health patient per year, mainly due to hospitalizations, medication and insurances database, which covers 90% of the French nursing care costs. Total per capita annual costs were lowest for population. An algorithm was used to select patients with patients receiving metformin monotherapy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics - Open Springer Journals

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis

Download PDF
11 pages

Loading next page...
 
/lp/springer_journal/direct-medical-costs-of-type-2-diabetes-in-france-an-insurance-claims-geCz0Eb7ci
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes
ISSN
2509-4262
eISSN
2509-4254
DOI
10.1007/s41669-017-0050-3
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics Open (2018) 2:209–219 https://doi.org/10.1007/s41669-017-0050-3 OR IGINAL RESEARCH ARTIC L E Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis 1 2 3 4 • • • • Bernard Charbonnel Dominique Simon Jean Dallongeville Isabelle Bureau 5 5 6 4 • • • Sylvie Dejager Laurie Levy-Bachelot Julie Gourmelen Bruno Detournay Published online: 7 August 2017 The Author(s) 2017. This article is an open access publication Abstract 12.5; 53.9% male) matched with a control group of 76,406 Objectives Our objects was to estimate the direct health- individuals without diabetes. Overall per patient per year care costs of type 2 diabetes mellitus (T2DM) in France in medical expenditures were €6506 ± 10,106 in the T2DM 2013. group as compared with €3668 ± 6954 in the control group. Methods Data were drawn from a random sample of The cost difference between the two groups was €2838 per &600,000 patients registered in the French national health patient per year, mainly due to hospitalizations, medication and insurances database, which covers 90% of the French nursing care costs. Total per capita annual costs were lowest for population. An algorithm was used to select patients with patients receiving metformin monotherapy

Journal

PharmacoEconomics - Open – Springer Journals

Published: Aug 7, 2017

References

  • Prévalence du diabète traité pharmacologiquement et disparités territoriales en France en 2012
    Mandereau-Bruno, L; Denis, P; Fagot-Campagna, AF; Fosse-Edorh, S
  • Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    Nathan, DM; Buse, JB; Davidson, MB; Ferrannini, E; Holman, RR; Sherwin, R
  • French national health insurance information system and the permanent beneficiaries sample
    Tuppin, P; Roquefeuil, L; Weill, A; Ricordeau, P; Merlière, Y
  • Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns—a cohort study
    Dupouy, J; Fournier, JP; Jouanjus, E; Palmaro, A; Poutrain, JC; Oustric, S
  • Healthcare service utilisation costs attributable to rheumatoid arthritis in France: analysis of a representative national claims database
    Fautrel, B; Cukierman, G; Joubert, JM; Laurendeau, C; Gourmelen, J; Fagnani, F
  • Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort
    Vorilhon, C; Chenaf, C; Mulliez, A; Pereira, B; Clerfond, G; Authier, N
  • Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database
    Detournay, B; Halimi, S; Robert, J; Deschaseaux, C; Dejager, S
  • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Inzucchi, SE; Bergenstal, RM; Buse, JB; Diamant, M; Ferrannini, E; Nauck, M; Peters, AL; Tsapas, A; Wender, R; Matthews, DR
  • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    Inzucchi, SE; Bergenstal, RM; Buse, JB; Diamant, M; Ferrannini, E; Nauck, M; Peters, AL; Tsapas, A; Wender, R; Matthews, DR
  • International classification of diseases 10th revision
  • The economic impact of diabetes
    Jönsson, B
  • Estimating the national and global costs of diabetes
    Williams, R
  • Coût des soins remboursés par l’Assurance maladie aux personnes traitées pour diabète : Etudes Entred 2001 et 2007
    Ricci, P; Chantry, M; Detournay, B; Poutignat, N; Kusnik-Joinville, O; Raimond, V
  • Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001
    Robert, J; Roudier, C; Poutignat, N; Fagot-Campagna, A; Weill, A; Rudnichi, A
  • Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes
    Detournay, B; Simon, D; Guillausseau, PJ; Joly, D; Verges, B; Attali, C
  • Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
    Tsilidis, KK; Kasimis, JC; Lopez, DS; Ntzani, EE; Ioannidis, JP
  • The myth regarding the high cost of end-of-life care
    Aldridge, M; Kelley, AS
  • Economic costs of diabetes in USA in 2012